Citizens reiterates CRISPR Therapeutics stock rating on Casgevy sales
Covered in this story
Analyst targets on Crispr Therapeutics AG
- Citizens JMP: $54.1 → $80 by Sep 2027 · Market Outperform via Investing.com
- Morgan Stanley: $48.4 → $60 by Jul 2027 · Equal Weight via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CRSP yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Crispr Therapeutics AG →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.